论文部分内容阅读
目的:探讨阿托伐他汀强化治疗对冠心病患者血脂和血管内皮功能的影响。方法:选取2016年1月—2017年4月喀什地区第一人民医院收治的冠心病患者90例作为研究对象,按入院顺序分组,单号为观察组,双号为对照组,每组45例。两组患者均给予冠心病二级预防基础治疗,在此基础上,对照组患者给予阿托伐他汀10 mg、1日1次,观察组患者给予阿托伐他汀40 mg、1日1次。比较两组患者治疗前后血脂指标、血管内皮功能指标水平及不良反应发生情况。结果:治疗后,两组患者高密度脂蛋白胆固醇水平明显高于治疗前,差异有统计学意义(P<0.05),但两组间的差异无统计学意义(P>0.05)。治疗后,观察组患者低密度脂蛋白胆固醇、总胆固醇、三酰甘油及内皮素水平分别为(2.25±0.53)、(4.76±0.62)、(1.48±0.44)mmol/L及(50.43±6.50)pg/ml,分别明显低于对照组的(2.76±0.46)、(5.36±0.57)、(1.82±0.38)mmol/L及(69.42±7.08)pg/ml;观察组患者内皮依赖性血管舒张功能、一氧化氮水平分别为(7.92±0.68)%、(79.10±9.59)μmol/L,分别明显高于对照组的(5.87±0.69)%、(57.64±8.13)μmol/L,差异均有统计学意义(P<0.05)。两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:阿托伐他汀强化治疗冠心病,能改善患者血脂代谢和血管内皮功能,安全性较好。
Objective: To investigate the effects of atorvastatin on blood lipid and endothelial function in patients with coronary heart disease. Methods: From January 2016 to April 2017, 90 patients with coronary heart disease admitted to the First People’s Hospital of Kashi Prefecture were enrolled in this study. Patients were divided into two groups according to hospital admission order: observation group and double number as control group, with 45 cases in each group . Both groups were given secondary prevention of coronary heart disease. On this basis, the patients in the control group were given atorvastatin 10 mg once daily on the 1st day. Patients in the observation group were given atorvastatin 40 mg once daily on the 1st day. The levels of serum lipids, the level of endothelial function and the incidence of adverse reactions before and after treatment were compared between the two groups. Results: After treatment, the levels of high density lipoprotein cholesterol in the two groups were significantly higher than those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). After treatment, the levels of LDL cholesterol, total cholesterol, triglyceride and endothelin in the observation group were (2.25 ± 0.53), (4.76 ± 0.62), (1.48 ± 0.44) mmol / L and (50.43 ± 6.50) (2.76 ± 0.46), (5.36 ± 0.57), (1.82 ± 0.38) mmol / L and (69.42 ± 7.08) pg / ml respectively in the control group. The endothelium-dependent vasodilatation (7.92 ± 0.68)%, (79.10 ± 9.59) μmol / L respectively, which were significantly higher than those of the control group (5.87 ± 0.69)% and (57.64 ± 8.13) μmol / L respectively Significance (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Atorvastatin treatment of coronary heart disease, can improve blood lipid metabolism and vascular endothelial function, safety is better.